CASI Pharmaceuticals, Inc. (NASDAQ: CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of innovative therapeutics and pharmaceutical products in China, the United States, and globally. Incorporated in 1991, the company has reoriented its business strategy towards China, establishing a robust infrastructure that includes sales and marketing, medical affairs, regulatory and clinical development, and manufacturing.

CASI Pharmaceuticals' primary business activities revolve around the Hematology/Oncology segment, with a product portfolio that includes EVOMELA, FOLOTYN, and CNCT19. EVOMELA is an intravenous formulation of melphalan used for the treatment of multiple myeloma, while FOLOTYN is a dihydrofolate reductase inhibitor indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. CNCT19 is an autologous anti-CD19 T-cell therapy product used for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia.

The company's revenue is generated through the commercialization of its products. Aside from EVOMELA, FOLOTYN, and CNCT19, CASI Pharmaceuticals has an exclusive China license and distribution rights to a novel formulation of thiotepa, a chemotherapeutic agent. Additionally, the company has entered into license agreements with Juventas, BioInvent International AB, and Cleave Therapeutics, Inc. for the development and commercialization of its products.

CASI Pharmaceuticals operates in a competitive market, with several other companies developing and commercializing similar products. However, the company's focus on China and its partnerships with local companies have positioned it well in this market.

The company's products are marketed to hospitals, clinics, and research institutions in China, as well as pharmaceutical companies and research institutions in the United States and Europe. CASI Pharmaceuticals relies on third-party distributors to distribute its approved medicines and has established relationships with sole distributors for its in-licensed products in China.

CASI Pharmaceuticals' intellectual property portfolio includes patents and patent applications related to its product candidates, as well as trademarks and trade secrets. The company generally seeks patent protection for its technology and product candidates in China, the United States, Canada, and other key markets.

In terms of regulations, the company's research, development, testing, manufacture, labeling, sale, marketing, advertising, and distribution of therapeutics in the United States, China, and other countries are subject to extensive regulations by federal, state, local, and foreign governmental authorities. The company must comply with the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act in the United States, as well as regulations in China and other countries where it operates.

In China, the National Medical Products Administration (NMPA) monitors and supervises the administration of pharmaceutical products, medical appliances, and equipment, and cosmetics. The company is subject to regulation and oversight by the NMPA and other authorities in China.

The company conducts preclinical research and clinical trials in compliance with relevant regulatory guidelines, including the Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) guidelines. The company's clinical trials are conducted in three sequential phases, including Phase 1, Phase 2, and Phase 3 clinical trials, and Phase 4 clinical trials may be conducted at the post-marketing surveillance stage.